Login
$MGTX
$8.74 -$0.44 (4.79%) Live

$MGTX SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
12 Nov 2026 S-3ASR
12 Nov 2026 10-Q
12 Nov 2026 8-K: Results of Operations and Financial Condition

LONDON and NEW YORK, November 12, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the third quarter e...

20 Oct 2026 Form 4: Giroux Richard, CFO & COO

Sold 56,000 shares ($557K)

20 Oct 2026 144
06 Oct 2026 Form 4: Naylor Stuart, CHIEF SCI OFCR, OPHTHALMOLOGY

Sold 27,659 shares ($294K)

06 Oct 2026 144
24 Sep 2026 Form 4: Sebulsky Alan, Director

Granted 100,000 Restricted Share Units

24 Sep 2026 Form 3: Sebulsky Alan, Director

Holds 34,500 shares of Ordinary Shares

23 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

LONDON and NEW YORK, September 23, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the appointment of Alan M. Sebulsky to its Board of Dire...

18 Aug 2026 Form 4: Forbes Alexandria, Director

Sold 62,000 shares ($859K)

18 Aug 2026 144
14 Aug 2026 SCHEDULE 13G/A
13 Aug 2026 S-8
13 Aug 2026 10-Q
13 Aug 2026 8-K: Results of Operations and Financial Condition

Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe grade 2/3 radiation-induced xerostomia

21 Jul 2026 Form 4: Giroux Richard, CFO & COO

Sold 56,000 shares ($701K)

21 Jul 2026 144
07 Jul 2026 Form 4: Naylor Stuart, CHIEF SCI OFCR, OPHTHALMOLOGY

Sold 27,659 shares ($409K)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support